National Tumor Assistance (ANT) Foundation, Bologna, Italy.
National Tumor Assistance (ANT) Foundation, Bologna, Italy.
Nutrition. 2021 Oct;90:111264. doi: 10.1016/j.nut.2021.111264. Epub 2021 Apr 7.
Malnutrition negatively affects the quality of life, survival, and clinical outcome of patients with cancer. Home artificial nutrition (HAN) is an appropriate nutritional therapy to prevent death from cachexia and to improve quality of life, and it can be integrated into a home palliative care program. The choice to start home enteral nutrition (HEN) or home parenteral nutrition (HPN) is based on patient-specific indications and contraindications. The aim of this observational study was to analyze the changes that occurred in the criteria for choosing the access route to artificial nutrition during 30 y of activity of a nutritional service team (NST) in a palliative home care setting, as well as to compare indications, clinical nutritional outcomes, and complications between HEN and HPN.
The following parameters were analyzed and compared for HEN and HPN: tumor site and metastases; nutritional status (body mass index, weight loss in the past 6 mo); basal energy expenditure and oral food intake; Karnofsky performance status; access routes to HEN (feeding tubes) and HPN (central venous catheters); water and protein-calorie support; and survival and complications of HAN.
From 1990 to 2020, HAN was started in 1014 patients with cancer (592 men, 422 women; 65.6 ± 12.7 y of age); HPN was started in 666 patients (66%); and HEN was started in 348 patients (34%). At the end of the study, 921 patients had died, 77 had suspended HAN for oral refeeding and 16 were in the progress of HAN. The oral caloric intake was <50% basal energy expenditure in all patients: 721 (71.1%) were unable to eat at all (HEN 270, HPN 451), whereas in 293 patients (28.9%), artificial nutrition was supplementary to oral intake. From 2010 to 2020, the number of central venous catheters for HPN, especially peripherally inserted central catheters, doubled compared with that in the previous 20 y, with a decrease of 71.6% in feeding tubes for HEN. At the beginning, patients on HEN and HPN had comparable nutrition and performance status, and there was no difference in nutritional outcome after 1 mo of HAN. In 215 patients who started supplemental parenteral nutrition to oral feeding, total protein-calorie intake allowed a significant increase in body mass index and Karnofsky performance status. The duration of HEN was longer than that of HPN but was similar to that of supplemental parenteral nutrition.
Over 30 y of nutritional service team activity, the choice of central venous catheters as an access route to HAN increased progressively and significantly due to personalized patient decision-making choices. Nutritional efficacy was comparable between HEN and HPN. In patients who maintained food oral intake, supplemental parenteral nutrition improved weight, performance status, and survival better than other types of HAN.
营养不良会降低癌症患者的生活质量、生存率和临床结局。家庭人工营养(HAN)是一种适当的营养治疗方法,可预防恶病质导致的死亡,并改善生活质量,且可纳入家庭姑息治疗方案。选择开始肠内营养(HEN)或肠外营养(HPN)取决于患者的具体适应证和禁忌证。本观察性研究的目的是分析在姑息治疗家庭护理环境中,营养服务团队(NST)30 年活动期间,选择人工营养途径的标准发生的变化,并比较 HEN 和 HPN 的适应证、临床营养结局和并发症。
分析并比较 HEN 和 HPN 的以下参数:肿瘤部位和转移部位;营养状况(体重指数、过去 6 个月体重减轻);基础能量消耗和口服食物摄入;卡诺夫斯基表现状态;HEN(喂养管)和 HPN(中央静脉导管)的入路;水和蛋白质-热量支持;以及 HAN 的生存和并发症。
1990 年至 2020 年,共为 1014 例癌症患者(592 例男性,422 例女性;65.6±12.7 岁)启动了 HAN;为 666 例患者(66%)启动了 HPN;为 348 例患者(34%)启动了 HEN。研究结束时,921 例患者死亡,77 例因口服喂养而暂停 HAN,16 例正在进行 HAN。所有患者的口服热量摄入均低于基础能量消耗的 50%:721 例(71.1%)完全无法进食(HEN 270 例,HPN 451 例),而在 293 例患者(28.9%)中,人工营养是口服摄入的补充。2010 年至 2020 年,HPN 用的中央静脉导管数量(尤其是外周插入的中央导管)比前 20 年增加了一倍,HEN 用的喂养管数量减少了 71.6%。开始时,HEN 和 HPN 患者的营养和表现状态相当,HAN 治疗 1 个月后营养结局无差异。在开始补充肠外营养以口服喂养的 215 例患者中,总蛋白质-热量摄入使体重指数和卡诺夫斯基表现状态显著增加。HEN 的持续时间长于 HPN,但与补充肠外营养的持续时间相似。
在 30 多年的营养服务团队活动中,由于个体化的患者决策选择,中央静脉导管作为 HAN 入路的选择逐渐增加并显著增加。HEN 和 HPN 的营养效果相当。在维持食物口服摄入的患者中,补充肠外营养在改善体重、表现状态和生存方面优于其他类型的 HAN。